Your Partner From Targets To Therapeutics

Discover Your Next Therapeutic Candidate

Fully Human Antibody Sequence Library

Off-the-shelf Preclinical & Clinical Assets

Fully Human Antibody Discovery Platforms

RenBiologics Achievements & Milestones​

0 +
Therapeutic Antibody Agreements
0 +
Target-nominated RenMice Licensing Projects
0 K+
Fully-human Antibody Sequences

BioMice Achievements & Milestones​

0 +
Custom Models Provided
0 +
Off-the-shelf Products
0 +
Drug Evaluation Projects Completed

Technology Platforms

Industry-leading technologies that accelerate drug discovery

mAb Platform

Our best-in-class fully human antibody mice de-risk your therapeutic antibody discovery.

Bispecific ADC Platform

Antibodies derived from RenLite mice against 200+ TAA targets are available for BsADC generation.

Anti-GPCR Antibody Platform

KO RenMice provide a solution for challenging GPCR targets with complex multi-pass transmembrane structure.

Nanobody Platform

RenNano-derived antibodies can infiltrate tumor tissues, cross the blood-brain barrier, or be constructed into other therapies.

CRO Products and Services

Models & services to get you from target to therapeutic candidate

Animal & Cell Models (BIOMICE)

We offer the most comprehensive collection of humanized models to evaluate efficacy of human immunotherapies.

Gene Editing Services

From point mutation knock-in alleles to transgenics, we deliver quality custom animal and cell models.

Efficacy & Toxicity Services

Comprehensive preclinical PK/PD, in vivo, and in vitro evaluation of novel test articles.

RenBiologics

Common light chain mAbs targeting tumor-associated antigens are assembled into bispecific antibodies (BsAb) with a low mismatch rate and ideal physiochemical properties. This approach allows for simultaneous targeting of multiple tumor-driven proteins, offering a potential solution to drug resistance. Moreover, recognition of cells co-expressing both targets enhances tumor specificity while minimizing off-target toxicity.

Renmice

RenMab™ mice contain the entire human immunoglobulin variable domain, which streamlines discovery and eliminates the need for humanization. Our RenLite® model contains a fixed common light chain that eliminates chain mispairing during bispecific antibody development. Immunized RenMice undergo in vivo selection and affinity maturation to generate quality antibody hits.

Biocytogen provides hundreds of genetically modified off-the-shelf BioMice for basic and preclinical research. Our large collection of humanized immune-checkpoint, humanized cytokine/cytokine receptor, humanized TAA mice, and immunodeficient mice, which have been published in hundred of studies, facilitate in vivo efficacy assessments of novel anti-human immunotherapies.

Biocytogen

Your Premier Partner for Drug Discovery

Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.

Biocytogen

Your Premier Partner for Drug Discovery

Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.

Cutting Edge Technologies

Founded in 2009, our proprietary, efficient genetic engineering technologies have made us a global leader in animal and cell model generation. Development of our advanced chromosome engineering technology and high-throughput antibody discovery platform further expanded our capabilities for therapeutic antibody discovery using our fully human antibody mice.

With the largest catalog of humanized models available and an experienced in vivo pharmacology team, we have completed over 1,300 drug evaluation projects. Our fast turnaround times and dedication to superior customer service have set us apart. 

Whether you need gene editing or pharmacology services, our cutting-edge platforms provide fast and reliable solutions.

Back to top